EP4201403A1 — Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
Assigned to Som Innovation Biotech SA · Expires 2023-06-28 · 3y expired
What this patent protects
The present invention relates to a compound selected from the group consisting of Tirapazamine and Quazinone, or a pharmaceutically acceptable salt thereof, and to combinations thereof, for use in the treatment or prevention of a GM2 gangliosidosis.
USPTO Abstract
The present invention relates to a compound selected from the group consisting of Tirapazamine and Quazinone, or a pharmaceutically acceptable salt thereof, and to combinations thereof, for use in the treatment or prevention of a GM2 gangliosidosis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.